Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
LOS ANGELES, Feb. 07, 2024 (GLOBE NEWSWIRE) -- AutoTech Breakthrough, a leading market intelligence organization that recognizes the top companies, technologies and products in the global automotive...
-
New data show additional improvement and stabilization in clinical outcomes in MPS II with 104 weeks of tividenofusp alfa (DNL310) treatment in the open-label, single-arm Phase 1/2 study; sustained...
-
Munich, Germany and West Seneca, NY, USA, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Infineon Technologies AG (FSE: IFX / OTCQX: IFNNY) has announced a collaboration with Worksport Ltd. (Nasdaq: WKSP;)....
-
CAMBRIDGE, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host...
-
SAN DIEGO, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...
-
Baltic Horizon Fond avaldab intressimäära, mis kohaldub fondi 5-aastastele võlakirjadele (ISIN: EE3300003235) järgmisel 3-kuulisel intressiperioodil, mis algab 8. veebruaril. Eelnevalt viidatud...
-
Baltic Horizon Fund publishes interest rate applicable to the fund’s 5-year bonds (ISIN: EE3300003235) for the next 3-months interest period which starts on 8 February 2024. The annual interest rate...
-
Baltic Horizon Fund publishes interest rate applicable to the fund’s 5-year bonds (ISIN: EE3300003235) for the next 3-months interest period which starts on 8 February 2024. The annual interest rate...
-
BOSTON and ATLANTA, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase...
-
Annual Report for 2023for ROCKWOOL A/SRelease no. 01 – 2024to Nasdaq Copenhagen 7 February 2024 Satisfactory performance in a difficult environment Highlights Sales in 2023 reached 3620 MEUR, a...